LYON, France & NEW YORK--(BUSINESS WIRE)--The Medicrea Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device ...
Innovations in medicine continue to push the edge of the envelope. I recently had the opportunity to speak with Rick Kienzle, Chief Commercial and Business Development Officer, at Medicrea. Medicrea ...
LYON, France & NEW YORK--(BUSINESS WIRE)--MEDICREA ®, (Paris:ALMED) (Alternext Paris: FR0004178572 - ALMED) the only medical device company offering patient-specific implant solutions for the ...
Medicrea announced agreements which raised €20 million ($22.4 million) to support the U.S. market penetration and international commercialization of its UNiD Patient-Specific Rods. Medicrea also ...
Please provide your email address to receive an email when new articles are posted on . Medicrea announced it has received FDA approval for the reportedly first patient-specific UNiD cervical rod for ...
Please provide your email address to receive an email when new articles are posted on . The Medicrea Group announced it will implement a lifetime warranty on its patient-specific UNiD technology, ...
The Medicrea Group has received 510(k) clearance from the U.S. Food & Drug Administration for its UNiD HUB product, a data-driven digital portal for the company’s Adaptive Spine Intelligence ...
LYON, France & NEW YORK--(BUSINESS WIRE)-- The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market – MRNTF), pioneering the digital transformation of spinal surgery ...
France's Medicrea Group said it has received FDA clearance for the world's first patient-specific spinal osteosynthesis rod, the UNiD, enabling physicians to order customized rods that match the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results